2. At all times relevant to the Board’s investigative findings in this case, the
Respondent, an intensivist, was employed by Hospital A in Berlin, Maryland.’ The
Respondent is board-certified in critical care medicine and pulmonary disease.

3. On or about August 14, 2017, the Board received a Mandated 10-day Report
from Hospital A (the “complaint”) stating that the Respondent's privileges had been
summarily suspended for impairment at work.2

4. After receiving the complaint, the Board initiated an investigation. Shortly
thereafter, the Board notified the Respondent of its investigation and requested a written
response to the allegations.

5. On or about August 24, 2017, the Respondent submitted a written response to
the complaint, whereby she acknowledged that she had consumed a substance during
work hours.

6. Board staff subpoenaed the Respondent's quality assurance and medical files
from Hospital A and conducted interviews of the Respondent and several witnesses.

7. The Board’s investigation revealed that on or about July 26, 2017, the
Respondent had voluntarily undergone an evaluation by the Maryland Physicians
Health Program (“MPHP”) and MPHP had developed a comprehensive treatment plan.?
At the time, the Respondent was working as a physician at Hospital A.

8. Shortly thereafter, on or about August 2, 2017, the Respondent had been

assigned to care for eight patients at Hospital A, five of whom were intensive care

ee

+ In order to maintain confidentiality, facility, patient and employee names will not be used in this
document, but will be provided to the Respondent on request.

2 On or about September 7, 2017, Hospital A terminated the summary suspension and placed the
Respondent on a medical leave of absence.

3 To maintain confidentiality, specific information regarding the Respondent's evaluation by MPHP and
any subsequent treatment will not be referenced in this document.

2
